• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肺淋巴管平滑肌瘤病(LAM)中基质金属蛋白酶(MMPs)及其组织抑制剂(TIMPs)的免疫组织化学研究

Immunohistochemical study of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in pulmonary lymphangioleiomyomatosis (LAM).

作者信息

Hayashi T, Fleming M V, Stetler-Stevenson W G, Liotta L A, Moss J, Ferrans V J, Travis W D

机构信息

Pulmonary-Critical Care Medicine Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892-1518, USA.

出版信息

Hum Pathol. 1997 Sep;28(9):1071-8. doi: 10.1016/s0046-8177(97)90061-7.

DOI:10.1016/s0046-8177(97)90061-7
PMID:9308732
Abstract

To evaluate the role of matrix metalloproteinases (MMPs) and their specific tissue inhibitors (TIMPs) in the pathogenesis of the structural damage and cystic lesions found in pulmonary lymphangioleiomyomatosis (LAM), immunohistochemical studies were made of the localization of MMP-1, MMP-2, MMP-3, MMP-9, TIMP-1, TIMP-2, HMB-45, and type IV collagen in sections of lung biopsy specimens from four patients with this disorder. These studies showed increased immunoreactivity compared with that in normal bronchiolar and vascular smooth muscle cells, of MMP-2 and, to a lesser extent, MMP-9 and MMP-1 in the LAM cells. MMP-2 was also localized in some elastic fibers and in the basement membranes of LAM cells and overlying epithelial cells. The basement membranes in both of these sites often showed colocalization of MMP-2 and type IV collagen. Some epithelial basement membranes showing this colocalization were disrupted. These changes were not accompanied by increased immunoreactivity for TIMPs. Taken together with previous observations showing structural damage to elastic fibers and collagen fibrils, and with the absence of demonstrable neutrophil or pancreatic types of elastase, these findings suggest that MMP-2 and MMP-9 (both of which can degrade elastin as well as collagens) are responsible for the connective tissue destruction and cyst formation in LAM.

摘要

为评估基质金属蛋白酶(MMPs)及其特异性组织抑制剂(TIMPs)在肺淋巴管平滑肌瘤病(LAM)中结构损伤和囊性病变发病机制中的作用,对4例该疾病患者肺活检标本切片中的MMP-1、MMP-2、MMP-3、MMP-9、TIMP-1、TIMP-2、HMB-45和IV型胶原进行了免疫组织化学研究。这些研究显示,与正常细支气管和血管平滑肌细胞相比,LAM细胞中MMP-2以及程度较轻的MMP-9和MMP-1的免疫反应性增加。MMP-2还定位于一些弹性纤维以及LAM细胞和覆盖其上的上皮细胞的基底膜中。这两个部位的基底膜常显示MMP-2和IV型胶原共定位。一些显示这种共定位的上皮基底膜被破坏。这些变化并未伴有TIMP免疫反应性增加。结合先前显示弹性纤维和胶原纤维结构损伤的观察结果,以及未检测到明显的中性粒细胞或胰腺型弹性蛋白酶,这些发现表明MMP-2和MMP-9(二者均可降解弹性蛋白以及胶原)是LAM中结缔组织破坏和囊肿形成的原因。

相似文献

1
Immunohistochemical study of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in pulmonary lymphangioleiomyomatosis (LAM).肺淋巴管平滑肌瘤病(LAM)中基质金属蛋白酶(MMPs)及其组织抑制剂(TIMPs)的免疫组织化学研究
Hum Pathol. 1997 Sep;28(9):1071-8. doi: 10.1016/s0046-8177(97)90061-7.
2
Immunohistochemical study of metalloproteinases and their tissue inhibitors in the lungs of patients with diffuse alveolar damage and idiopathic pulmonary fibrosis.弥漫性肺泡损伤和特发性肺纤维化患者肺部金属蛋白酶及其组织抑制剂的免疫组织化学研究
Am J Pathol. 1996 Oct;149(4):1241-56.
3
Expression and in-situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer.胰腺癌中细胞外基质蛋白及细胞外基质降解蛋白酶编码基因的表达与原位定位
Int J Cancer. 1995 Aug 9;62(4):407-13. doi: 10.1002/ijc.2910620409.
4
Matrix metalloproteinases and tissue inhibitors of metalloproteinases in human gliomas.人胶质瘤中的基质金属蛋白酶和金属蛋白酶组织抑制剂
J Neurosurg. 1995 Aug;83(2):298-307. doi: 10.3171/jns.1995.83.2.0298.
5
Role of the matrix metalloproteinase and tissue inhibitors of metalloproteinase families in noninvasive and invasive tumors transplanted in mice with severe combined immunodeficiency.基质金属蛋白酶和金属蛋白酶组织抑制剂家族在移植到严重联合免疫缺陷小鼠体内的非侵袭性和侵袭性肿瘤中的作用。
Urology. 1998 May;51(5):849-53. doi: 10.1016/s0090-4295(98)00010-7.
6
The distribution of matrix metalloproteinases and tissue inhibitor of metalloproteinases in colorectal cancer.基质金属蛋白酶及其组织抑制剂在结直肠癌中的分布
Surg Oncol. 1995 Feb;4(1):21-9. doi: 10.1016/s0960-7404(10)80027-1.
7
Higher concentrations of matrix metalloproteinases in bronchoalveolar lavage fluid of patients with adult respiratory distress syndrome.成人呼吸窘迫综合征患者支气管肺泡灌洗术中基质金属蛋白酶浓度较高。
Am J Respir Crit Care Med. 1997 Jan;155(1):43-6. doi: 10.1164/ajrccm.155.1.9001287.
8
Immunohistochemical study of transforming growth factor-beta 1, matrix metalloproteinase-2,9, tissue inhibitors of metalloproteinase-1,2, and basement membrane components at pancreatic ducts in chronic pancreatitis.慢性胰腺炎时胰腺导管中转化生长因子-β1、基质金属蛋白酶-2、9、金属蛋白酶组织抑制剂-1、2及基底膜成分的免疫组织化学研究
Pancreas. 1998 Nov;17(4):412-8. doi: 10.1097/00006676-199811000-00013.
9
Matrix metalloproteinases and their tissue inhibitors in the lesions of cardiac and pulmonary sarcoidosis: an immunohistochemical study.心脏和肺部结节病病变中基质金属蛋白酶及其组织抑制剂:一项免疫组织化学研究
Hum Pathol. 2002 Dec;33(12):1158-64. doi: 10.1053/hupa.2002.129423.
10
Spatiotemporal expression patterns of metalloproteinases and their inhibitors in the postnatal developing rat cerebellum.金属蛋白酶及其抑制剂在出生后发育中的大鼠小脑中的时空表达模式。
J Neurosci. 1999 Jun 15;19(12):4994-5004. doi: 10.1523/JNEUROSCI.19-12-04994.1999.

引用本文的文献

1
mTOR pathway diseases: challenges and opportunities from bench to bedside and the mTOR node.mTOR信号通路疾病:从实验室到临床的挑战与机遇以及mTOR节点
Orphanet J Rare Dis. 2025 May 27;20(1):256. doi: 10.1186/s13023-025-03740-1.
2
Extracellular vesicles modulate integrin signaling and subcellular energetics to promote pulmonary lymphangioleiomyomatosis metastasis.细胞外囊泡调节整合素信号传导和亚细胞能量代谢以促进肺淋巴管平滑肌瘤病转移。
Res Sq. 2025 Mar 20:rs.3.rs-5390547. doi: 10.21203/rs.3.rs-5390547/v1.
3
The development for emerging biomarkers of lymphangioleiomyomatosis.
淋巴管平滑肌瘤病新兴生物标志物的研究进展。
Orphanet J Rare Dis. 2024 Nov 29;19(1):445. doi: 10.1186/s13023-024-03455-9.
4
Lymphangioleiomyomatosis: Searching for potential biomarkers.淋巴管平滑肌瘤病:寻找潜在生物标志物
Front Med (Lausanne). 2023 Feb 2;10:1079317. doi: 10.3389/fmed.2023.1079317. eCollection 2023.
5
Differential Modulation of Matrix Metalloproteinases-2 and -7 in LAM/TSC Cells.淋巴管平滑肌瘤病/结节性硬化症细胞中基质金属蛋白酶-2和-7的差异调节
Biomedicines. 2021 Nov 24;9(12):1760. doi: 10.3390/biomedicines9121760.
6
Protease activity sensors enable real-time treatment response monitoring in lymphangioleiomyomatosis.蛋白酶活性传感器可实时监测淋巴管肌瘤病的治疗反应。
Eur Respir J. 2022 Apr 14;59(4). doi: 10.1183/13993003.00664-2021. Print 2022 Apr.
7
Tuberous sclerosis complex for the pulmonologist.肺科医生须知的结节性硬化症。
Eur Respir Rev. 2021 Aug 3;30(161). doi: 10.1183/16000617.0348-2020. Print 2021 Sep 30.
8
Heterogeneity and Cancer-Related Features in Lymphangioleiomyomatosis Cells and Tissue.淋巴管肌瘤病细胞和组织中的异质性和癌症相关特征。
Mol Cancer Res. 2021 Nov;19(11):1840-1853. doi: 10.1158/1541-7786.MCR-21-0220. Epub 2021 Jul 26.
9
Exploring the Role of Matrix Metalloproteinases as Biomarkers in Sporadic Lymphangioleiomyomatosis and Tuberous Sclerosis Complex. A Pilot Study.探索基质金属蛋白酶作为散发性淋巴管平滑肌瘤病和结节性硬化症生物标志物的作用:一项初步研究。
Front Med (Lausanne). 2021 Apr 26;8:605909. doi: 10.3389/fmed.2021.605909. eCollection 2021.
10
Raising the Flag for Mast Cells as a Novel Target in Lymphangioleiomyomatosis.将肥大细胞作为淋巴管平滑肌瘤病的新靶点予以关注。
Am J Respir Crit Care Med. 2021 Aug 15;204(4):387-389. doi: 10.1164/rccm.202104-0872ED.